Legese A Mekuria1,2,3,4, Jan M Prins4, Alemayehu W Yalew3, Mirjam A G Sprangers1, Pythia T Nieuwkerk1. 1. Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Epidemiology, Netherlands Institute for Health Sciences/Erasmus University Medical Center, Rotterdam, The Netherlands. 3. School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia. 4. Division of Infectious Diseases, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: Combination antiretroviral therapy (cART) suppresses viral replication to an undetectable level if a sufficiently high level of adherence is achieved. We investigated which adherence measurement best distinguishes between patients with and without detectable viral load in a public ART programme without routine plasma viral load monitoring. METHOD: We randomly selected 870 patients who started cART between May 2009 and April 2012 in 10 healthcare facilities in Addis Ababa, Ethiopia. Six hundred and sixty-four (76.3%) patients who were retained in HIV care and were receiving cART for at least 6 months were included and 642 had their plasma HIV-1 RNA concentration measured. Patients' adherence to cART was assessed according to self-report, clinician recorded and pharmacy refill measures. Multivariate logistic regression model was fitted to identify the predictors of detectable viremia. Model accuracy was evaluated by computing the area under the receiver operating characteristic (ROC) curve. RESULT: A total of 9.2% and 5.5% of the 642 patients had a detectable viral load of ≥40 and ≥400 RNA copies/ml, respectively. In the multivariate analyses, younger age, lower CD4 cell count at cART initiation, being illiterate and widowed, and each of the adherence measures were significantly and independently predictive of having ≥400 RNA copies/ml. The ROC curve showed that these variables altogether had a likelihood of more than 80% to distinguish patients with a plasma viral load of ≥400 RNA copies/ml from those without. CONCLUSION: Adherence to cART was remarkably high. Self-report, clinician recorded and pharmacy refill non-adherence were all significantly predictive of detectable viremia. The choice for one of these methods to detect non-adherence and predict a detectable viral load can therefore be based on what is most practical in a particular setting.
OBJECTIVE: Combination antiretroviral therapy (cART) suppresses viral replication to an undetectable level if a sufficiently high level of adherence is achieved. We investigated which adherence measurement best distinguishes between patients with and without detectable viral load in a public ART programme without routine plasma viral load monitoring. METHOD: We randomly selected 870 patients who started cART between May 2009 and April 2012 in 10 healthcare facilities in Addis Ababa, Ethiopia. Six hundred and sixty-four (76.3%) patients who were retained in HIV care and were receiving cART for at least 6 months were included and 642 had their plasma HIV-1 RNA concentration measured. Patients' adherence to cART was assessed according to self-report, clinician recorded and pharmacy refill measures. Multivariate logistic regression model was fitted to identify the predictors of detectable viremia. Model accuracy was evaluated by computing the area under the receiver operating characteristic (ROC) curve. RESULT: A total of 9.2% and 5.5% of the 642 patients had a detectable viral load of ≥40 and ≥400 RNA copies/ml, respectively. In the multivariate analyses, younger age, lower CD4 cell count at cART initiation, being illiterate and widowed, and each of the adherence measures were significantly and independently predictive of having ≥400 RNA copies/ml. The ROC curve showed that these variables altogether had a likelihood of more than 80% to distinguish patients with a plasma viral load of ≥400 RNA copies/ml from those without. CONCLUSION: Adherence to cART was remarkably high. Self-report, clinician recorded and pharmacy refill non-adherence were all significantly predictive of detectable viremia. The choice for one of these methods to detect non-adherence and predict a detectable viral load can therefore be based on what is most practical in a particular setting.
Authors: Tamsin K Phillips; Ira B Wilson; Kirsty Brittain; Allison Zerbe; Claude A Mellins; Robert H Remien; Catherine Orrell; Elaine J Abrams; Landon Myer Journal: J Acquir Immune Defic Syndr Date: 2019-03-01 Impact factor: 3.731
Authors: Emily W Paolillo; Assawin Gongvatana; Anya Umlauf; Scott L Letendre; David J Moore Journal: Alcohol Clin Exp Res Date: 2017-07-05 Impact factor: 3.455
Authors: Johanna Boretzki; Eva Wolf; Carmen Wiese; Sebastian Noe; Annamaria Balogh; Anja Meurer; Ivanka Krznaric; Alexander Zink; Christian Lersch; Christoph D Spinner Journal: Patient Prefer Adherence Date: 2017-11-08 Impact factor: 2.711
Authors: R L Cook; Z Zhou; N E Kelso-Chichetto; J Janelle; J P Morano; C Somboonwit; W Carter; G E Ibanez; N Ennis; C L Cook; R A Cohen; B Brumback; K Bryant Journal: Addict Sci Clin Pract Date: 2017-09-27
Authors: Oladele Vincent Adeniyi; Anthony Idowu Ajayi; Daniel Ter Goon; Eyitayo Omolara Owolabi; Alfred Eboh; John Lambert Journal: BMC Infect Dis Date: 2018-04-13 Impact factor: 3.090
Authors: Sabrina K Been; Elif Yildiz; Pythia T Nieuwkerk; Katalin Pogány; David A M C van de Vijver; Annelies Verbon Journal: PLoS One Date: 2017-11-09 Impact factor: 3.240